Bictegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg Taffic Tablet
HIV-1 infection
| Product | Bictegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg Taffic Tablet |
|---|---|
| Used for | HIV-1 infection |
| Dosage form | Tablet |
| Pack | Standard manufacturer pack |
| Manufacturer | Hetero Healthcare Limited |
| Composition | Bictegravir (50 mg) + Emtricitabine (200 mg) + Tenofovir Alafenamide (25 mg) |
| Pack size | 30 Tablets |
| Packaging | Bottle |
| Shelf life | 2 years |
| Storage | Store below 30°C, away from light and moisture. |
| Country of origin | India |
No payment is taken on this site. We reply with price, batch, expiry and shipping cost. Ask about this product on WhatsApp
Bictegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg Taffic Tablet is a tablet in our HIV Care range, used for hiv-1 infection.
TAFFIC is a fixed dose combination product (three-drug) containing 50 mg of bictegravir (BIC), 200 mg of emtricitabine (FTC), and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of TAFFIC is one tablet taken orally once daily with or without food. TAFFIC is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to Bictegravir, Emtricitabine and Tenofovir Alafenamide.
Antiretroviral single agents and fixed-dose combinations.
This is a prescription medicine and must be used under the supervision of a registered medical practitioner.
